This post is from a suggested group
Investigating the Pharmacological and Non-Pharmacological Treatment Modalities for Autosomal Dominant Polycystic Kidney
Autosomal Dominant Polycystic Kidney Disease ($\text{ADPKD}$) is a common inherited disorder characterized by the growth of numerous fluid-filled cysts within the kidneys, leading to progressive enlargement of the organs, subsequent decline in renal function, and ultimately, kidney failure in the majority of affected individuals over their lifetime.
Historically, treatment was limited to managing complications like hypertension, pain, and recurrent infections, but significant therapeutic progress has been made with the introduction of disease-modifying agents that actively target the cellular mechanisms responsible for cyst growth and proliferation, offering hope for slowing disease progression.
The primary driver of cyst growth in $\text{ADPKD}$ is the abnormal proliferation of renal tubular epithelial cells and the secretion of fluid into the cyst lumen, processes that are often mediated by elevated levels of cyclic adenosine monophosphate ($\text{cAMP}$). The most significant therapeutic breakthrough has been the development of vasopressin $\text{V}_2$ receptor antagonists (e.g., tolvaptan), which inhibit $\text{cAMP}$ signaling…
